The effects of a novel non‐invasive application of platelet‐rich fibrin on periodontal clinical parameters and gingival crevicular fluid transforming growth factor‐β and collagen‐1 levels: A randomized, controlled, clinical study

Abstract

Background Several potential benefits have been attributed to the platelet‐rich fibrin (PRF), including enhanced tissue healing properties. In this study, we hypothesized that the application of PRF as an adjunct to conventional scaling and root planing (ScRp) would enhance the outcomes of non‐surgical periodontal therapy. Methods The present study was a split‐mouth randomized controlled clinical trial design in 24 deep periodontal pockets in 12 patients with periodontitis. The pockets were randomly assigned as test or control. The test group received PRF as an adjunct to ScRp, whereas the control group received ScRp only. We measured periodontal clinical parameters at baseline, 3, and 6 months after the treatments. To study the initial healing in response to treatment, transforming growth factor‐β (TGF‐β) and collagen‐1 (Col‐1) in gingival crevicular fluid (GCF) were measured using enzyme‐linked immunosorbent assay at baseline, third, seventh, and 14th days. Results The test group showed a significantly greater pocket reduction, higher clinical attachment gain, and less gingival recession than the control group at 3 and 6 months. The test Col‐1 levels (1.27 ± 1.05, 1.35 ± 0.76, 0.97 ± 0.53 ng/site) and TGF‐β levels (11.93 ± 2.68, 12.54 ± 3.66, 17.19 ± 11.66 pg/site) were higher than the control Col‐1 levels (0.76 ± 0.20, 0.84 ± 0.24, 0.57 ± 0.19 ng/site) and TGF‐β levels (6.34 ± 1.67, 6.35 ± 3.44, 7.51 ± 2.85 pg/site) at all measurement days respectively. Conclusions Non‐surgical application of the PRF as an adjunct to conventional ScRp may effectively improve the periodontal clinical parameters via increasing expression of the GCF TGF‐β and Col‐1 levels.

The efficacy of non‐surgical platelet‐rich fibrin application on clinical periodontal parameters and periostin level in periodontitis: Clinical trial

“…Özcan, E.,et al showed that the average of PPD at sites treated with ScRp+PRF were 2.57 ± 0.75 mm at 3 months. 26 The bolded numbers refer to statistically significant differences (p < 0.05 and p < 0.01).…”

“…control groups which were 2.57 ± 0.75 and 0.93 ± 0.49 mm respectively. 26 For sample size calculation, G power software (v. 3.1.9.6) was used with 95% confidence interval and margin of error of 5%.…”

Clinical Efficacy of Repeated Applications of Local Drug Delivery and Adjunctive Agents in Nonsurgical Periodontal Therapy: A Systematic Review

“…To date, hyaluronic acid and enamel matrix derivatives have been registered as medical devices under FDA, whereas, aPDT used in dentistry comprises of a chemical agent (photosensitizer dye) and a medical device (laser) component. Recently, biological mediators such as polypeptide growth factors have also been introduced for use as an adjunct in nonsurgical periodontal therapy [16,17].…”

Effects of collagen membranes and bone substitute differ in periodontal ligament cell microtissues and monolayers

“…During periodontal tissue regeneration, collagen-type-I (COL1A1) 17 and periostin (POSTN) 18 play a crucial role, while vascular endothelial growth factor (VEGF) 19 and angiogenin (ANG) 20 are known for their importance in angiogenesis and finally interleukin (IL)6 and IL8 21 mediate the periodontal inflammatory process. Thus, it is of utter importance for material development in periodontal GTR to understand which in vitro model is the most suitable to test novel or optimized membranes and bone substitute materials in terms of regeneration.…”

“…Ideally, an in vitro model for GTR research that mimics patient‐side periodontal ligament should not only be a 3D construct, but also be capable to deliver information on biocompatibility, cell adhesion and production of molecular biomarkers for regeneration, angiogenesis and inflammation. During periodontal tissue regeneration, collagen‐type‐I (COL1A1) 17 and periostin (POSTN) 18 play a crucial role, while vascular endothelial growth factor (VEGF) 19 and angiogenin (ANG) 20 are known for their importance in angiogenesis and finally interleukin (IL)6 and IL8 21 mediate the periodontal inflammatory process. Thus, it is of utter importance for material development in periodontal GTR to understand which in vitro model is the most suitable to test novel or optimized membranes and bone substitute materials in terms of regeneration.…”